It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The new program includes upstream and downstream process development and large-scale GMP production.
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
Subscribe To Our Newsletter & Stay Updated
